GLP-1

Uncovering Ozempic: The Mysterious $10 Fat-Burning Supplement Taking Amazon by Storm

by

Brazilian Lean Gains Momentum as Consumers Seek Affordable Weight-Loss Solutions Amazon sellers have reported a surge in demand for Brazilian Lean, a thermogenic fat-burner marketed as a budget-friendly alternative to prescription weight-loss treatments. The supplement, sold by Dr Vitamin Solutions, claims to boost metabolism and curb appetite through a blend of caffeine, kelp powder, and … Read more

The Most Troubling Trend in Men’s Health, According to Doctors

by

Men increasingly turn to online gray markets for longevity treatments like peptides, GLP-1 weight-loss drugs, and testosterone without medical supervision, risking severe health consequences. Board-certified urologist Dr. David Shusterman warns that bypassing physician oversight for hormone and metabolic medicine can lead to dangerous side effects, including prostate complications, blood clots, and fertility loss. The Risks … Read more

Healthcare Professionals Face Disciplinary Action Over Recalled iDEXIS Drugs

by

South African health regulators—the South African Health Products Regulatory Authority (SAHPRA), the South African Pharmacy Council (SAPC), and the Health Professions Council of South Africa (HPCSA)—have issued a stern warning to medical professionals: continuing to prescribe, dispense, or stock recalled iDEXIS weight-loss injections will result in formal disciplinary action. The products, which include various formulations … Read more

Online GLP-1 Prescriptions Often Bypass Meaningful Clinician Interaction

by

Researchers at Yale University found that patients can obtain GLP-1 prescriptions from online platforms in as little as five minutes using fake profiles, raising significant concerns about the level of clinical oversight in direct-to-consumer healthcare. A study published July 6 in the JAMA medical journal revealed that 45 out of 49 websites tested issued prescriptions … Read more

Surprising Benefit of Weight Loss Meds for Women

by

Unemployed women who begin taking GLP-1 weight-loss medications like Ozempic or Wegovy experience a 27% increase in their employment rate within 18 months, according to a working paper from the National Bureau of Economic Research (NBER). Harvard economist Rebecca Diamond, who analyzed survey data from over 10,000 adults, found that these gains appear tied to … Read more

New Pilot Program Offers Affordable GLP-1 Medications

by

Kinney Drugs will launch the Medicare GLP-1 Bridge Program next Wednesday, providing eligible Medicare Part D patients access to weight-loss medications like Wegovy, Zepbound, and Fundayo for a $50 monthly copay through 2027. According to Shannon Miller, vice president of healthcare operations at Kinney Drugs, the pilot program aims to bridge the coverage gap for … Read more

GLP-1 Medications Linked to Lower Risk of Violent Behavior, Rutgers Study Finds

by

New research from Rutgers University indicates that individuals using GLP-1 medications—such as Ozempic and Wegovy—may experience a reduced likelihood of engaging in violent behavior. A study of 821 participants found that the well-established link between impulsivity and violence significantly weakens among those currently prescribed these drugs, suggesting a potential neurological mechanism that calms reactive responses. … Read more

GLP-1 Supplements and Nutrition: Meeting the New Metabolic Health Demand

by

The rising adoption of GLP-1 receptor agonists (RAs) is triggering a major pivot in the food and supplement sectors, as manufacturers race to develop companion products for weight-loss patients. Approximately 12% of U.S. adults have utilized these therapies, according to industry data. Experts from companies like Gnosis by Lesaffre, Kerry, and ADM report that this … Read more

Could Ozempic Be a Secret Weapon for ADHD?

by

Patients taking GLP-1 receptor agonists, such as Ozempic and Wegovy, are reporting unexpected improvements in ADHD symptoms, including increased focus, reduced procrastination, and better impulse control. While no clinical trials currently substantiate these claims, Dr. Lenard Adler, director of the Adult ADHD Program at NYU Langone Health, confirms he has observed these anecdotal reports among … Read more

© 2026 Newsy Today. All rights reserved.


For contact, advertising, copyright, issues email: [email protected]

For contact, advertising, copyright, issues email: [email protected]